Crossmark

Independent validation of the PrecivityAD2™ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment

Crossref DOI link: https://doi.org/10.1038/s44400-025-00026-y

Published Online: 2025-09-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Coppinger, Justine

West, Tim https://orcid.org/0000-0003-3267-8249
Kirmess, Kris M.

Fogelman, Ilana https://orcid.org/0000-0001-8550-7625
Ray, Sutapa

Verghese, Philip B.

Braunstein, Joel B. https://orcid.org/0000-0002-1155-0206
Yarasheski, Kevin E. https://orcid.org/0000-0001-5436-2451
,
Funding

Funding for this research was provided by:

National Institutes of Health (R44 AG059489)

BrightFocus Foundation (CA2016636)

Gerald and Henrietta Rauenhorst Foundation

Alzheimer’s Drug Discovery Foundation (GC-201711-2013978)

National Institute on Aging (U19AG024904)
License Information

Text and Data Mining valid from 2025-09-04

Version of Record valid from 2025-09-04
More Information

Article History

Received: 18 April 2025

Accepted: 17 July 2025

First Online: 4 September 2025

Competing interests

: All C2N co-authors are salaried employees or consultants with equity interests in C2N Diagnostics and have contributed to the development of the PrecivityAD2 test.

Document is current

Any future updates will be listed below